Kimberly-Clark Corporation has announced that Joseph Romanelli, president of Human Health International for Merck & Co, (MSD) has been elected to its board of directors, effective immediately. In connection with the election, Kimberly-Clark's board size will increase from 12 to 13 directors.

"Joe Romanelli is an outstanding addition to the Kimberly-Clark board of directors," said Mike Hsu, chairman and chief executive officer of Kimberly-Clark. "As we advance our powering care strategy, we will benefit from Romanelli’s global leadership experience and his expertise in using leading-edge science to save and improve lives around the world."

Romanelli has served as president of human health international for MSD, a global healthcare company that develops and manufactures medicines, vaccines, biologic therapies, and animal health products, since 2022. In this role, he oversees MSD's 75-plus markets outside of the US and leads a team of 14,000 colleagues. Prior to joining MSD, Romanelli served as the chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company. Previously, he served in a variety of strategic and operational roles with increasing responsibility at MSD and Schering-Plough for 25 years.